Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - Cyclacel Pharmaceuticals, Inc.tv489461_ex32-2.htm
EX-32.1 - EXHIBIT 32.1 - Cyclacel Pharmaceuticals, Inc.tv489461_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - Cyclacel Pharmaceuticals, Inc.tv489461_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - Cyclacel Pharmaceuticals, Inc.tv489461_ex31-1.htm
10-K - FORM 10-K - Cyclacel Pharmaceuticals, Inc.tv489461-10k.htm
Exhibit 23.1​
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements (Nos. 333-219055, 333-205153, 333-183483, and 333-143786) on Form S-8 and (Nos. 333-211046 and 333-187801) on Form S-3 of Cyclacel Pharmaceuticals, Inc. of our report dated March 30, 2018, relating to the consolidated financial statements of Cyclacel Pharmaceuticals, Inc. and subsidiaries, appearing in this Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the year ended December 31, 2017.
/s/ RSM US LLP
New York, New York
March 30, 2018